Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Breakthrough Device Authorizations Cross 200 As Q3 Data Show Steady Designation Pace

1 September 2026 · By · Wire by Fusion42

Published

1 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at insights.citeline.com →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

The U.S. FDA has authorised over 200 breakthrough medical devices by Q3 2026, maintaining a steady pace of designations that underline its ongoing support for innovative medical technology.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can accelerate U.S. medical device market entry as the FDA scales approvals for breakthrough technologies. Now is key to sharpen dev and regulatory processes to capitalise on this steady designation pace.

◆ Coverage

1 source · 1 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfdabreakthrough-devicesmedtechregulatory-update